Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS
- 1GI Diseases Research Unit, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada
- 2Department of Radiology, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada
- Correspondence to Dr Stephen Vanner, GI Diseases Research Unit, Kingston General Hospital, Queen's University, 76 Stuart Street, Kingston, Ontario, Canada;
- Revised 21 October 2010
- Accepted 24 October 2010
- Published Online First 26 November 2010
Objectives Recent studies using the lactulose hydrogen breath test (LHBT) suggest most patients with irritable bowel syndrome (IBS) have small intestinal bacterial overgrowth (SIBO). However, the validity of the LHBT has been questioned, particularly as this test could reflect changes in oro-caecal transit. Therefore, we combined oro-caecal scintigraphy with LHBT in 40 patients who were Rome II positive for IBS to determine if the increase in hydrogen is due to the test meal reaching the caecum.
Design Patients ingested the test meal containing 99mTc and 10 g lactulose and simultaneous measurements of the location of the test meal using scintigraphic scanning and breath hydrogen levels were obtained every 10 min for 3 h. The LHBT was considered positive when the rise in H2 above baseline was >20 ppm within 90 and/or 180 min. The combined test was negative for SIBO if ≥5% of the test meal was in the caecum at the time the LHBT was positive.
Results 63% had an abnormal LHBT at 180 min and 35% at 90 min. The oro-caecal transit time based on scintigraphic scanning ranged from 10 to 220 min and correlated with IBS sub-type. At the time of increase in H2, the % accumulation of 99mTc in the caecum was ≥5% in 88% of cases (22/25).
Conclusions These findings demonstrate that an abnormal rise in H2 measured in the LHBT can be explained by variations in oro-caecal transit time in patients with IBS and therefore do not support the diagnosis of SIBO.
Funding SV is supported by an operating grant from the Canadian Institutes of Health Research and a Crohn's and Colitis Foundation of Canada research scientist award. D. Yu received a resident research award from Physician Services Incorporation (PSI) of Ontario.
Competing interests None.
Ethics approval This study was conducted with the approval of the Queen's University Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.